Holdings

Invesco Biotechnology & Genome ETF

As of Jul 31, 2026, Invesco Biotechnology & Genome ETF reported 29 positions worth US$278M. Largest: Regeneron Pharmaceuticals, Inc., Amgen Inc. and CareDx, Inc. What it bought and sold, with each filing.

Holdings

Part of
Invesco
Positions
29
Value as reported
US$278M
Holdings as of
Jul 31, 2026
Last filed
Sep 28, 2026
CompanySharesValue as reported% of portfolioChangeAs of
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
20,233US$15.4M5.5%+3,549Jul 31, 2026
Amgen Inc.
NASDAQ:AMGN
38,223US$14.7M5.2%+4,572Jul 31, 2026
CareDx, Inc.
NASDAQ:CDNA
325KUS$14.2M5.0%−39,886Jul 31, 2026
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
29,460US$14.1M5.0%NewJul 31, 2026
Royalty Pharma plc
NASDAQ:RPRX
238KUS$13.9M4.9%+83,631Jul 31, 2026
Biogen Inc.
NASDAQ:BIIB
66,507US$13.5M4.8%+482Jul 31, 2026
Gilead Sciences, Inc.
NASDAQ:GILD
96,026US$12.5M4.4%+8,762Jul 31, 2026
United Therapeutics Corporation
NASDAQ:UTHR
22,197US$11.5M4.1%−5,015Jul 31, 2026
Bio-Techne Corp
NASDAQ:TECH
146KUS$10.5M3.7%+24,015Jul 31, 2026
Illumina, Inc.
NASDAQ:ILMN
48,231US$9.89M3.5%−56,601Jul 31, 2026
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
70,055US$9.57M3.4%−10,360Jul 31, 2026
Vericel Corporation
NASDAQ:VCEL
200KUS$9.21M3.3%+16,572Jul 31, 2026
Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
43,457US$8.93M3.2%+4,751Jul 31, 2026
Incyte Corporation
NASDAQ:INCY
72,136US$8.62M3.1%−55,363Jul 31, 2026
Repligen Corporation
NASDAQ:RGEN
60,807US$8.57M3.0%+8,624Jul 31, 2026
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
329KUS$8.52M3.0%+43,677Jul 31, 2026
Halozyme Therapeutics, Inc.
NASDAQ:HALO
102KUS$8.41M3.0%+2,049Jul 31, 2026
Qiagen N.V.
NYSE:QGEN
197KUS$8.16M2.9%+52,189Jul 31, 2026
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
132KUS$7.95M2.8%+20,236Jul 31, 2026
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
44,979US$7.5M2.7%−8,681Jul 31, 2026
Exelixis, Inc.
NASDAQ:EXEL
140KUS$7.43M2.6%−15,538Jul 31, 2026
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
827KUS$7.43M2.6%−96,495Jul 31, 2026
Veracyte, Inc.
NASDAQ:VCYT
158KUS$7.34M2.6%−38,468Jul 31, 2026
Collegium Pharmaceutical, Inc.
NASDAQ:COLL
207KUS$7.34M2.6%+51,774Jul 31, 2026
Omeros Corporation
NASDAQ:OMER
601KUS$7.12M2.5%NewJul 31, 2026
PTC Therapeutics, Inc.
NASDAQ:PTCT
104KUS$7.04M2.5%+1,664Jul 31, 2026
AnaptysBio, Inc.
NASDAQ:ANAB
121KUS$6.47M2.3%NewJul 31, 2026
Sarepta Therapeutics, Inc.
NASDAQ:SRPT
420KUS$6.24M2.2%NewJul 31, 2026
Ardelyx, Inc.
NASDAQ:ARDX
1.12MUS$5.55M2.0%NewJul 31, 2026